These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 29501603)
1. Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery. Gomes EC; Falci DR; Bergo P; Zavascki AP; Rigatto MH Int J Antimicrob Agents; 2018 Jul; 52(1):86-89. PubMed ID: 29501603 [TBL] [Abstract][Full Text] [Related]
2. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066 [TBL] [Abstract][Full Text] [Related]
3. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. Rigatto MH; Behle TF; Falci DR; Freitas T; Lopes NT; Nunes M; Costa LW; Zavascki AP J Antimicrob Chemother; 2015 May; 70(5):1552-7. PubMed ID: 25604744 [TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen. Okoduwa A; Ahmed N; Guo Y; Scipione MR; Papadopoulos J; Eiras DP; Dubrovskaya Y Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844039 [TBL] [Abstract][Full Text] [Related]
5. Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B. John JF; Falci DR; Rigatto MH; Oliveira RD; Kremer TG; Zavascki AP Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038262 [TBL] [Abstract][Full Text] [Related]
6. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin. Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560 [TBL] [Abstract][Full Text] [Related]
7. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B. Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846 [TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Mendes CA; Cordeiro JA; Burdmann EA Ann Pharmacother; 2009 Dec; 43(12):1948-55. PubMed ID: 19887593 [TBL] [Abstract][Full Text] [Related]
9. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. Kubin CJ; Ellman TM; Phadke V; Haynes LJ; Calfee DP; Yin MT J Infect; 2012 Jul; 65(1):80-7. PubMed ID: 22326553 [TBL] [Abstract][Full Text] [Related]
10. [Risk factors for acute kidney injury in patients treated with polymyxin B experience from 139 cases at a tertiary university hospital in Colombia]. Osorio J; Barreto J; Samboni CF; Cándelo LA; Álvarez LC; Benavidez S; Téllez RP; Santofimio D; Ramos JA; Gómez CA Rev Chilena Infectol; 2017 Feb; 34(1):7-13. PubMed ID: 28394975 [TBL] [Abstract][Full Text] [Related]
11. Polymyxin B and colistin-the economic burden of nephrotoxicity against multidrug resistant bacteria. Tuon FF; Rocha JL; Gasparetto J J Med Econ; 2019 Feb; 22(2):158-162. PubMed ID: 30466325 [TBL] [Abstract][Full Text] [Related]
12. Risk of polymyxin B-induced acute kidney injury with a non adjusted dose versus adjusted dose based on renal function. Zheng G; Cai J; Zhou S; Du N; Bai H; He J; Bian X Per Med; 2022 Jul; 19(4):307-314. PubMed ID: 35762314 [No Abstract] [Full Text] [Related]
13. Acute kidney injury associated with colistin sulfate vs. polymyxin B sulfate therapy: A real-world, retrospective cohort study. Zhang Y; Dong R; Huang Y; Ling X; Ye Z; Jiang S Int J Antimicrob Agents; 2024 Jan; 63(1):107031. PubMed ID: 37951480 [TBL] [Abstract][Full Text] [Related]
14. Non-recovery from dialysis-requiring acute kidney injury and short-term mortality and cardiovascular risk: a cohort study. Lee BJ; Hsu CY; Parikh RV; Leong TK; Tan TC; Walia S; Liu KD; Hsu RK; Go AS BMC Nephrol; 2018 Jun; 19(1):134. PubMed ID: 29890946 [TBL] [Abstract][Full Text] [Related]
15. Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. McDonald RJ; McDonald JS; Carter RE; Hartman RP; Katzberg RW; Kallmes DF; Williamson EE Radiology; 2014 Dec; 273(3):714-25. PubMed ID: 25203000 [TBL] [Abstract][Full Text] [Related]
16. [Analysis of risk factors of polymyxin B-associated acute kidney injury in intensive care unit patients with severe infection]. Wang Y; Chen X; Guo X; Cao K; Zhu Z; Zhang B; Liang P; Yu W Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Jun; 32(6):716-720. PubMed ID: 32684219 [TBL] [Abstract][Full Text] [Related]
17. Risk factors for polymyxin B-associated acute kidney injury. Chang K; Wang H; Zhao J; Yang X; Wu B; Sun W; Huang M; Cheng Z; Chen H; Song Y; Chen P; Chen X; Gan X; Ma W; Xing L; Wang Y; Cao B Int J Infect Dis; 2022 Apr; 117():37-44. PubMed ID: 35108608 [TBL] [Abstract][Full Text] [Related]
18. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Vardakas KZ; Falagas ME Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609 [TBL] [Abstract][Full Text] [Related]
19. Incidence, dynamics, and prognostic value of acute kidney injury for death after cardiac surgery. Dardashti A; Ederoth P; Algotsson L; Brondén B; Bjursten H J Thorac Cardiovasc Surg; 2014 Feb; 147(2):800-7. PubMed ID: 24100099 [TBL] [Abstract][Full Text] [Related]
20. Risk of Nephrotoxicity Associated With Nonrenally Adjusted Intravenous Polymyxin B Compared to Traditional Dosing. Maniara BP; Healy LE; Doan TL J Pharm Pract; 2020 Jun; 33(3):287-292. PubMed ID: 30253682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]